Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03106298 · ClinicalTrials.gov registry record
Iron Deficiency and FGF23 Regulation in CKD and HF
A clinical trial of Chronic Kidney Diseases and Iron Deficiency Anemia, sponsored by Northwestern University.
- Completed
- Registry status
- 77
- Enrollment target
- 1
- Study location
NCT03106298: Completed study of Chronic Kidney Diseases and Iron Deficiency Anemia, sponsored by Northwestern University.
NCT03106298 is a study of Chronic Kidney Diseases and Iron Deficiency Anemia that has completed, run by Northwestern University. The registered enrollment target is 77 participants, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03106298, a study of Chronic Kidney Diseases and Iron Deficiency Anemia, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates the effects of intravenous (IV) iron sucrose therapy on blood levels of Fibroblast Growth Factor 23 (FGF23, a protein that regulates the amount of phosphate in the body) in iron deficiency anemia in healthy participants, participants with Congestive Heart Failure (CHF, where the heart does not pump adequate blood supply to the body), participants with Chronic Kidney Disease (CKD, where the kidney function is reduced), and participants with CKD and CHF.
Primary Outcome
longitudinal change in plasma c-terminal FGF23 (RU/ml) over 6 weeks and 3 months
Conditions Studied
Interventions
- DRUG Iron Sucrose
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2015-12-18 |
| Est. Completion | 2018-08-01 |
What the finished NCT03106298 record still lists
NCT03106298 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (83% lower).
The record links to 3 conditions, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 1 intervention - of which Iron Sucrose is the first listed.
NCT03106298 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03106298 about?
NCT03106298 is a clinical study titled "Iron Deficiency and FGF23 Regulation in CKD and HF". This study investigates the effects of intravenous (IV) iron sucrose therapy on blood levels of Fibroblast Growth Factor 23 (FGF23, a protein that regulates the amount of phosphate in the body) in iron deficiency anemia in healthy participants, participants with Congestive Heart Failure (CHF, where ...
What is the current status of trial NCT03106298?
This trial is currently completed. The enrollment target is 77 participants. The study started on 2015-12-18. Estimated completion is 2018-08-01.
What conditions does trial NCT03106298 study?
This clinical trial studies the following conditions: Chronic Kidney Diseases, Iron Deficiency Anemia, Chronic Heart Failure.
What interventions are being tested in trial NCT03106298?
The interventions under investigation include: Iron Sucrose (DRUG).
Who is sponsoring clinical trial NCT03106298?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03106298 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03106298's enrollment target sits among peer trials
77 43rd of 73 higher than 31 of 73 other Chronic Kidney Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
RECRUITING · Phase 2
-
Mindfulness in Chronic Kidney Disease
RECRUITING · NA
-
Ferric Citrate and Chronic Kidney Disease in Children
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI